I was early in predicting that ImClone Systems would be bought for $70 a share, although I had no idea the acquiror would be Eli Lilly(LLY Quote).
As for columns and calls I wish I could take back, there was my prediction for a profitable sale of Middlebrook Pharmaceuticals(MBRK Quote) to some larger specialty pharmaceutical company. That takeout never happened. I was a big fan of Progenics(PGNX Quote) based on high hopes for the commercial launch of its bowel drug Relistor. Unfortunately, doctors haven't been as excited about the drug as me. I boldly predicted the October and December approval of AMAG Pharmaceuticals'(AMAG Quote) iron replacement therapy ferumoxytol. Neither happened, although I believe the third shot at approval early next year will be the charm. Or, so I hope. Grading that last call will have to wait for next year's report card. Happy New Year!- Loading Comments...
- Loading Comments...
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,023.42 | 1,069.30 | 2,112.44 | 35.03 |
Oil *
76.05
|
|
UP
17.46
|
UP
2.67
|
UP
7.12
|
DOWN
0.30
|
10 Yr
3.50%
SPDR Gold
107.43
|
|
+0.17%
|
+0.25%
|
+0.34%
|
-0.85%
|
Data delayed 20 minutes |














